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PSMB8 Encoding the b5i Proteasome Subunit Is Mutated
in Joint Contractures, Muscle Atrophy, Microcytic
Anemia, and Panniculitis-Induced Lipodystrophy Syndrome
Anil K. Agarwal,1 Chao Xing,2 George N. DeMartino,3 Dario Mizrachi,4 Maria Dolores Hernandez,5
Ana Berta Sousa,6 Laura Martı´nez de Villarreal,5 Heloı´sa G. dos Santos,6 and Abhimanyu Garg1,*
We performed homozygosity mapping in two recently reported pedigrees from Portugal and Mexico with an autosomal-recessive auto-
inflammatory syndrome characterized by joint contractures, muscle atrophy, microcytic anemia, and panniculitis-induced lipodystro-
phy (JMP). This revealed only one homozygous region spanning 2.4 Mb (5818 SNPs) on chromosome 6p21 shared by all three affected
individuals from both families. We directly sequenced genes involved in immune response located in this critical region, excluding the
HLA complex genes. We found a homozygous missense mutation c.224C>T (p.Thr75Met) in the proteasome subunit, beta-type,
8 (PSMB8) gene in affected patients from both pedigrees. The mutation segregated in an autosomal-recessive fashion and was not
detected in 275 unrelated ethnicallymatched healthy subjects. PSMB8 encodes a catalytic subunit of the 20S immunoproteasomes called
b5i. Immunoproteasome-mediated proteolysis generates immunogenic epitopes presented bymajor histocompatibility complex (MHC)
class I molecules. Threonine at position 75 is highly conserved and its substitution with methionine disrupts the tertiary structure of
PSMB8. As compared to normal lymphoblasts, those from an affected patient showed significantly reduced chymotrypsin-like proteo-
lytic activity mediated by immunoproteasomes.We conclude that mutations in PSMB8 cause JMP syndrome, most probably by affecting
MHC class I antigen processing.We recently reported a distinct autosomal-recessive syn-
drome presenting with joint contractures, muscle atrophy,
microcytic anemia, and panniculitis-induced childhood-
onset lipodystrophy (JMP) in three patients from two pedi-
grees.1 The lipodystrophy affected the face, arms, and
thorax initially and more severely than the abdomen and
lower extremities, which were affected later (Figure S1
available online). Although the patients did not have acan-
thosis nigricans, diabetes, or hyperinsulinemia, mild
metabolic disturbances such as borderline hypertriglyceri-
demia, markedly low levels of high-density lipoprotein
cholesterol, and mild elevations of liver enzymes were
noted. All the patients had hepato-splenomegaly and
hypergammaglobulinemia. Joint contractures initially
affected the hands and feet, which were more severely
deformed than the other joints.
Similar manifestations have been reported previously
from Japan in three patients who in addition presented
with fever, elevated erythrocyte sedimentation rate, mac-
roglossia, mental retardation, and calcification of basal
ganglia.2–5 The genetic basis of the JMP syndrome was
unknown and we had hypothesized that it belongs to
the group of inherited autoinflammatory diseases.6 By
using genome-wide homozygosity mapping, we now
report a homozygous missense mutation in the protea-
some subunit, b-type, 8 (PSMB8 [MIM 177046]) gene,
which encodes the b5i subunit (also known as large1The Division of Nutrition and Metabolic Diseases, Department of Internal M
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immunoproteasomes in patients with JMP syndrome.
Affected individuals and their family members were
recruited into our ongoing study of genetic basis of lipo-
dystrophies (Figure S2). The protocol was approved by the
InstitutionalReviewBoardofUTSouthwesternandHospital
de Santa Maria, and all the patients, their family members,
and healthy controls gave the written informed consent.
Genomic DNA was extracted from buffy coat or from
Epstein-Barr virus-transformed lymphoblastoid cell lines
via the Easy-DNA kit (Invitrogen, Carlsbad, CA). Genotyp-
ing was performed with the Illumina HumanOmni1-Quad
Beadchip by the Microarray Core Facility at UT South-
western. Allele calls were generated with GenomeStudio
version 1.5.16. Consanguinity was confirmed in family
JMP100 and suspected in family JMP200, suggesting a
recessive disease. Therefore, we carried out both classic
homozygosity mapping via linkage analysis7 and mod-
ern homozygosity mapping via identifying regions of
extended homozygosity. We chose 7296 single-nucleotide
polymorphisms (SNPs) from among the ~1 million SNPs
from the HumanOmni1-Quad chip to construct a sparse
linkage map, in which SNPs were spaced ~2 per centi-
Morgan. In family JMP200, we performed linkage analysis
with the sparse map under a recessive model by assuming
individuals JMP200.1 and JMP200.2 were first cousins, as
proposed by Hildebrandt et al.8 The analysis was doneedicine and the Center for Human Nutrition, University of Texas South-
nces, University of Texas Southwestern Medical Center, Dallas, TX 75390,
enter, Dallas, TX 75390, USA; 4Division of Endocrinology, Department of
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ic¸o de Gene´tica Me´dica, Hospital de Santa Maria, 1649-035 Lisbon, Portugal
Genetics. All rights reserved.
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Figure 1. Homozygous Region Shared
by Affected Individuals with JMP
Syndrome, Position of Candidate Genes
in the Region, Structure of PSMB8, and
Disease-Causing Mutation
(A) Homozygous region shared by the
affected individuals JMP 200.4, 200.3,
and 100.3. The B allele frequency is a
normalized measure of the allelic intensity
ratio of the two alleles, and deviation
from 0.5 indicates homozygosity. The
genomic position is based on NCBI36/
hg18 assembly. Each dot indicates the
SNP genotyped by means of the Illumina
HumanOmni1-Quad Beadchip. The ver-
tical lines for each panel indicate the
regions of homozygosity. Isolated hetero-
zygous SNPs within larger homozygous
segments are likely to represent miscalls.
(B) Position of some of the candidate genes
in the critical region identified by homozy-
gosity mapping. Tel, telomeric end; cent,
centromeric end. The critical region
spanned from 31.5 Mb to 34.0 Mb on
chromosome 6.
(C) Structure of PSMB8 and the location of
the mutation in the JMP patients. Human
PSMB8 contains six exons and five introns.
Also shown are the alternatively spliced
exons 1A and 1B. The mutation
c.224C>T in PSMB8 is located in exon 2.
(D) Sequence electropherogram for normal
sequence in exon 2 of PSMB8.
(E) Sequence from JMP 200.2 showing
heterozygous c.224C>T mutation.
(F) Sequence from JMP 200.3 showing
the homozygous c.224C>T mutation. The
amino acid substitution is shown below
the electropherogram.with MERLIN.9 We also screened for regions of extended
homozygosity in all individuals via PLINK.10
The genome-wide linkage scan in family JMP200
identified only one region on 6p21 spanning ~16.7 Mb
(~13.4 cM) with a positive lod score of 0.93 (Figure S3).
Across the genome, there was only one homozygous
region spanning 2.4 Mb (5818 SNPs) shared by all three
affected individuals from both families (Figure 1A) but
not by any unaffected. This homozygous region was
located under the linkage peak. There was no indication
of copy number variation in the region according to the
Log R Ratio. Excluding the HLA complex, ~200 genes are
located within this region, including those that are pre-
dicted or are of unknown function. Because we had
hypothesized that the JMP syndrome is an autoinflamma-
tory syndrome, we initially selected genes that might affect
the immune response (Figure 1B). These included PSMB8
and PSMB9 (proteasomal subunits also called b5i and b1i,The American Journal of Human Generespectively; MIM 177046 and
177045, respectively), TAP1 and TAP2
(transporters 1 and 2, ATP-binding
cassette, subfamily B associated with
antigen processing; MIM 170260 and170261, respectively), and TAPBP (TAP binding protein;
MIM 601962). We also selected PBX2 (pre-B cell leuke-
mia homeobox 2, a transcription factor; MIM 176311),
BTNL2 (butyrophilin-like 2, a member of the B7 family
of costimulatory molecules; MIM 606000), AIF1 (allograft
inflammatory factor 1, which is associated with rheuma-
toid arthritis; MIM 601833), and AGPAT1 (acylglycerol
phosphate acyltransferase, isoform 1, involved in triglyc-
eride biosynthesis; MIM 603099). The coding regions and
the splice site junctions of the genes in the critical region
were amplified with gene-specific primers located in
intronic regions (Table S1). Polymerase chain reaction
(PCR) was assembled as described earlier.11 The PCR pro-
duct was purified to remove primers and dNTPs and
sequenced with ABI Prism 3100.
We found a homozygous c.224C>T mutation in PSMB8
(NM_148919.3; MIM 177046) in the affected subjects from
both pedigrees (Figures 1C–1F). This mutation is predictedtics 87, 866–872, December 10, 2010 867
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Figure 2. Conservation of the Mutated
Residue across Species, Crystal Structure
of Normal and Mutant PSMB8, Proteaso-
mal Activity, and Expression of b5i in
Cell Lysates of Lymphoblasts from an
Affected Patient
(A) Alignment of partial PSMB8 amino acid
sequence around threonine at position 75
in human (NP_683720.2), chimpanzee
(XP_001167272.1), dog (XP_532100.1), cow
(NP_001035570.1), mouse (NP_034854.1),
and zebrafish (NP_571467.2). The conserved
residue threonine is highlighted in yellow.
Amino acids that are not conserved are
shown in red.
(B) Protein model for the wild-type
and mutant, Thr75Met, human PSMB8.
b sheets are shown in blue, helices in
orange, and unstructured loops in gray.
Threonine 73 and glycine 119 are the cata-
lytic amino acids. Mutation of threonine
75 to methionine widens the distance
between the catalytic threonine 73 and
glycine 119 by 1.2 Ǻ. All amino acids are
numbered according to transcript 1B.
(C) Proteasomal activity in EBV-trans-
formed lymphoblasts from a control
and an affected patient (JMP200.4).
The chymotrypsin-like, trypsin-like, and
PGPH-like proteolytic activities are ex-
pressed as fluorogenic units (F.U.) per mg
of protein. Each bar represents mean 5
SD from three independent experiments
carried out in duplicate. p values were
derived from the paired t test.
(D) Western blots. Total cell lysates from
EBV-transformed lymophoblasts of a con-
trol subject and an affected patient
(JMP200.4) were resolved on 10% SDS-
PAGE and probed with antibodies against
Rpt2 (an ATPase of the PA700, a 19S
proteasome regulatory particle), Rpn12 (a
subunit of 19S proteasome regulatory
subunit), a2, b5i, and b5 (subunits of 20S
proteasome), and a housekeeping protein
actin. The first two lanes on the left contain
purified 20S and PA700 proteins from
bovine red blood cells as positive controls.
The control and the patient contained the
same amount of b5i protein.to result in substitution of threonine at position 75 with
methionine (p.Thr75Met; numbering according to tran-
script 1B; NP_683720.2). The available parents and unaf-
fected siblings harbored the heterozygous mutation. No
other disease-causing variant was found on sequencing
of candidate genes in the region (Table S2). Genotyping
DNA of 275 healthy ethnically matched subjects of His-
panic origin from Dallas revealed no one harboring the
c.224C>T variant in PSMB8. We aligned genotypes of the
three affected from both families in the homozygous
region and identified a segment of 0.22 Mb covering
PSMB8 shared by all three affected (Table S3). This suggests
that the haplotypes shared by the affected subjects in both
families are identical-by-descent; however, the origin of
the mutation seems to be ancient.868 The American Journal of Human Genetics 87, 866–872, DecembThe threonine at position 75 of PSMB8 is highly
conserved across species (Figure 2A). Prediction of the
structure and conserved regions between highly homolo-
gous (>75%) human PSMB8 (protein ID NP_683720.2)
and yeast PSMB5 (ortholog of human b5, protein ID
NP_015428.1) via Clustal W analysis allowed us to manu-
ally exchange the amino acids in yeast PSMB5 (PDB
identification number 1z7q, chain L)12,13 with those repre-
sented exclusively in human PSMB8 via the PyMol pro-
gram (PyMOL Molecular Graphics System, Version
1.2r3pre, Schro¨dinger, LLC). For further optimization pro-
tocol, we used multiple step energy minimization and
molecular dynamics (MD) simulation to fully relax our
initial model. All simulations were carried out with the
Amber 9 program14 with force field (ff99) and periodicer 10, 2010
Table 1. Serum Cytokine Levels in Affected Patients
Serum Cytokine JMP 200.3 JMP 200.4
Reference Intervals
in (pg/mL)
IL-1b 27 18 0–36
IL-2 8 <5 0–12
IL-2 receptor 806 1316 0–1033
IL-4 6 <5 0–5
IL-5 6 5 0–5
IL-6 37 79 0–5
IL-8 46 8 0–5
IL-10 9 18 0–18
IL-12 8 6 0–6
IL-13 <5 <5 0–5
Interferon-g 14 17 0–5
TNF-a 6 <5 0–22
IL, interleukin; TNF, tumor necrosis factor. Abnormally high levels are indicated
in bold.boundary conditions.15 To simulate behavior in solution,
the protein was solvated with a 10 A˚ TIP3P octagon water
cap. Prior to MD simulations, two steps of minimization
were performed. First, the human PSMB8 was fixed and
only the positions occupied by water were minimized
followed by the minimization of the entire simulation
system. After energy minimization, a 100 picosecond
MD simulation was carried out under constant volume
conditions, and temperature was heated up continuously
from 0K to 300K. The time step of the simulations was
2.0 femtoseconds with a cutoff of 12 A˚ for nonbonded
interactions. The final conformations were obtained when
the total energy reached the minimum. The best structure
was examined with the Profile-3D16 and Procheck17 pro-
grams. Protein modeling of the Thr75Met substitution
showed that it relaxes PSMB8 by 1.2 A˚ and may affect
the proteolytic processing of peptides (Figure 2B).
Proteasome activity was determined in the cell lysates
of Epstein-Barr virus-transformed lymphoblasts from a
control subject and an affected patient (JMP200.4). Lym-
phoblasts were washed with PBS, pelleted by centrifuga-
tion, and lysed in four volumes of buffer consisting of
50 mM Tris-HCl (pH 7.8), 5 mM 2-mercaptoethanol, 1 mM
ATP, and 5 mM MgCl2. Lysates were cleared of cell debris
by centrifugation at 5000 3 g for 5 min. Proteasome activ-
ity was determined by hydrolysis of peptide substrates as
described previously.18 We employed three different pep-
tides that are specific, preferred substrates for three classes
of peptidases having chymotrypsin-like, trypsin-like, and
peptidyl glutamyl peptide-hydrolyzing (PGPH) activity.
In brief, cell extracts were incubated with 50 mM substrates
(succinyl-Leu-Leu-Val-Tyr-7-amino-4-methylcoumarin,
succinyl-Val-Leu-Arg-7-amino-4-methylcoumarin, or ben-
zyloxycarbonyl-Leu-Leu-Glu-7-amino-4-methylcoumarin)
for 20 min at 37C. The rate of amino-4-methylcoumarin
production, a direct measure of proteasome activity, was
monitored continuously by fluorescence detection at
360 nm excitation/480 nm emission, with a BioTek Syn-
ergy MX Plate reader. Steady-state rates of proteolysis
were expressed as arbitrary fluorescence units produced
per min of incubation and were normalized per mg of pro-
tein. Protein concentration was determined with the Brad-
ford method.19 We observed markedly reduced chymo-
trypsin-like activity but not trypsin-like or PGPH-like
activity in lymphoblast cell lysates from the patient with
JMP syndrome (Figure 2C). A marked reduction in the pro-
teasomal activity was observed in the presence of MG132,
a specific inhibitor of S26 proteasomes, when tested with
substrate succinyl-Leu-Leu-Val-Tyr-7-amino-4-methylcou-
marin, consistent with the presence of proteasomal
activity (Figure S4). This observationwas further confirmed
by determining the presence of key subunits of protea-
some/immunoproteasome by western blots. For western
blotting, 40 mg of total cellular protein from lymphoblast
cell lysates from the patient and control was resolved on
10% SDS-PAGE and transferred to nitrocellulose mem-
branes for immunoblotting with various primary anti-The Americanbodies against Rpt2 (an ATPase of the PA700, a 19S protea-
some regulatory particle), Rpn12 (a subunit of 19S
proteasome regulatory subunit), and a2, b5i, and b5
(subunits of 20S proteasome). All of the antibodies were
raised in-house as described previously,18,20 detected with
peroxidase-labeled secondary antibody, and exposed to
X-ray film. b-actin was used as a housekeeping gene and
loading control. No difference was observed in the expres-
sion of various components of the proteasomal units,
including b5i subunit in the cell lysates from the control
and patient (Figure 2D).
Therefore, this study suggests that a homozygous mis-
sense loss-of-function mutation in PSMB8 causes the JMP
syndrome. This conclusion is supported by the following
observations: (1) evidence of linkage to the 6p21.2 region
and homozygosity in the same region; (2) a homozygous
c.224C>T missense variant in PSMB8 in the two pedigrees;
(3) segregation of the c.224C>T mutation in other mem-
bers of the pedigrees in an autosomal-recessive fashion;
(4) no previous report of this variant as a SNP in any data-
base; (5) lack of this variant in ethnically matched healthy
controls; (6) substitution of methionine for the highly
conserved threonine at position 75 of PSMB8 disrupts
the tertiary structure of the protein; and (7) reduced
chymotrypsin-like proteasomal activity in cell lysates of
lymphoblasts from an affected patient.
To gain insight into the functional effects of the
p.Thr75Met variant, we measured serum interleukin (IL)
1b, 2, 4, 5, 6, 8, 10, 12, IL-2 receptor, interferon-g, and
tumor necrosis factor-a (ARUP Laboratories, Salt Lake
City, UT) in two affected patients from JMP200 pedigree,
which revealed that both affected patients had 7- to
19-fold increased levels of IL-6 and 2.8- to 3.5-fold elevated
levels of interferon g (Table 1). Whereas serum levels ofJournal of Human Genetics 87, 866–872, December 10, 2010 869
IL-8 were >9-fold elevated in JMP 200.3, in JMP200.4 only
1.6-fold elevation was observed. The levels of other cyto-
kines were not elevated in both patients. Marked elevation
of erythrocyte sedimentation rate and serum g globulins,
interferon-g, and IL-6 levels without elevation in other
cytokines such as IL-1 and TNF-a suggest not only an
ongoing inflammation but also a peculiar biomarker signa-
ture present in the JMP syndrome. Ongoing inflammation
was clearly evident in the patient JMP200.4 who hadmany
active skin lesions at the time of examination (Figure S1),
which were biopsy proven to be consistent with pannicu-
litis.
PSMB8 encodes b5i, a catalytic subunit of the immuno-
proteasome.21 Immunoproteasome-mediated proteolysis
generates immunogenic epitopes presented by major his-
tocompatibility complex (MHC) class I molecules. This
degradation follows covalent modification of the proteins
with polyubiquitin,22,23 which targets them to the 26S pro-
teasome. The 26S proteasome is composed of two subcom-
plexes: the 20S proteasome that contributes protease func-
tion and PA700 (19S regulator) that mediates translocation
of the attached substrates to the 20S proteasome. The 20S
proteasome is a 700,000 dalton complex composed of four
axially stacked heptameric rings. Each of the two identical
outer rings contains seven different a type subunits, and
each of the two identical inner rings contains seven
different b type subunits.23 The b1, b2, and b5 subunits
display different specificities for peptide bond hydrolysis
and have predominantly PGPH-, trypsin-, and chymo-
trypsin-like activities, respectively.22,24 Higher eukaryotes
contain isoforms of b1, b2, and b5, termed b1i, b2i, and
b5i, respectively, which are selectively incorporated into
immunoproteasomes. Immunoproteasomes are constitu-
tively expressed in cells of hematopoietic origin, particu-
larly lymphocytes and monocytes, but can be induced in
nonhematopoietic cells after exposure to inflammatory
cytokines such as interferon-g.21 Proteasomes and immu-
noproteasomes are functionally very similar, but not
identical. Immunoproteasomes stimulate cleavage after
hydrophobic, basic, and branched chain residues, while
suppressing cleavage after acidic residues,25–27 and thus
can potentially enhance the generation of some antigenic
epitopes differently from the proteasomes. However, a clear
distinction of the role of proteasomes and immunoprotea-
somes in immune response has not yet emerged.
Targeted gene deletion of Psmb8 in mice causes reduced
MHC class I cell surface expression and inefficient presen-
tation of the endogenous male antigen HY.28 These mice
are healthy, have normal T and B lymphocyte counts in
their lymphoid organs,28 and respond normally to chal-
lenge with lymphocytic choriomeningitis virus,29 but are
susceptible to infection with Toxoplasma gondii.30 The
patients with JMP syndrome, however, are not known to
be prone to infections. The lack of resemblance of the
phenotype of Psmb8/ mice to that observed in patients
with JMP syndrome may indicate different biology of the
PSMB8 in humans and mice. Further to this, our patients870 The American Journal of Human Genetics 87, 866–872, Decembhave only missense mutation, whereas in the mice the
whole gene is deleted. Nonetheless, further studies are
required to fully understand the underlying reasons for
discrepancy in the phenotype of patients with JMP
syndrome and Psmb8/ mice.
Recently, studies with PR-957, a selective inhibitor of b5i
(LMP7) that binds to the active site and specifically inhibits
chymotrypsin-like peptidase activity, have revealed a
unique role of PSMB8 in cytokine production.31 In endo-
toxin-stimulated peripheral blood mononuclear cells from
healthy subjects and from patients with rheumatoid
arthritis, PR-957 blocked production of IL-23 by ~80%
and of TNF-a and IL-6 by ~50%.31 Further, PR-957 amelio-
rated disease in two mouse models of arthritis.31 However,
our patients had hypergammaglobulinemia and extremely
high serum levels of IL-6 and interferon-g. These data
suggest that p.Thr75Met substitution may have additional
effects beyond a partial loss of function. This substitution
may alter the processing of an exogenous or endogenous
antigen so as to trigger an accelerated immune response tar-
geted most directly to adipose tissue, joints, and muscles.
So far, the monogenic autoinflammatory diseases have
been reported to be due to mutations in the family of
PYRIN domain-containing proteins, proteins interacting
with pyrin, and others, resulting in activation of the inter-
leukin-1b pathway.6 This report expands the spectrum
of autoinflammatory diseases to include JMP syndrome re-
sulting from altered immunoproteasome function. How
reduced chymotrypsin-like proteasomal activity resulting
from a loss-of-function PSMB8 mutation results in joint
contractures, panniculitis-induced lipodystrophy, and the
other clinical features of JMP syndrome remains to be
elucidated.Supplemental Data
Supplemental Data include four figures and three tables and can
be found with this article online at http://www.cell.com/AJHG/.Acknowledgments
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